文献速递脑血管病

氯吡格雷联合阿司匹林对比单用阿司匹林治疗急性轻中度卒中:ATAMIS随机临床试验

Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

ATAMIS多中心开放标签盲法终点随机试验纳入中国66家医院3000例48小时内急性轻中度缺血性卒中患者,比较氯吡格雷联合阿司匹林与单用阿司匹林。主要终点7天早期神经功能恶化在联合组1502例中发生72例(4.8%),单药组1413例中发生95例(6.7%),风险差-1.9%(95%CI,-3.6至-0.2;P=0.03),两组出血事件相似。作者认为双联抗血小板治疗可能是急性轻中度卒中的更优选择。

要点

  • 中国66家医院3000例急性轻中度缺血性卒中患者随机分组。
  • 7天早期神经功能恶化联合组4.8% vs 单药组6.7%,风险差-1.9%(95%CI,-3.6至-0.2;P=0.03)。
  • 两组出血事件相似,联合组在减少早期神经功能恶化方面优于单药组。

核心结论

  • 在中国急性轻中度缺血性卒中患者中,氯吡格雷联合阿司匹林在减少7天早期神经功能恶化方面优于单用阿司匹林,且安全性特征相似。
  • 作者认为双联抗血小板治疗可能是治疗急性轻中度卒中优于单用阿司匹林的选择。

研究设计与样本

  • 多中心、开放标签、盲法终点、随机临床试验,在中国66家医院开展,时间为2016年12月20日至2022年8月9日。
  • 最终随访日期为2022年10月30日,分析报告于2023年3月12日。
  • 3065例缺血性卒中患者中,排除65例不符合标准或无随机化结局者后,纳入3000例症状发作48小时内的急性轻中度卒中患者。
  • 患者按1:1随机分配至氯吡格雷联合阿司匹林组(n=1541)或单用阿司匹林组(n=1459)。
  • 主要终点为7天早期神经功能恶化,定义为NIHSS评分较基线增加2分或以上,且非脑出血所致。

主要发现

  • 3000例随机患者中,1942例(64.6%)为男性,平均(SD)年龄65.9(10.6)岁,入院时NIHSS评分中位数(IQR)为5(4-6),1830例(61.0%)为病因未明型卒中。
  • 改良意向性治疗分析共纳入2915例患者。
  • 早期神经功能恶化在双联抗血小板组1502例中发生72例(4.8%),在单用阿司匹林组1413例中发生95例(6.7%)(风险差-1.9%;95%CI,-3.6至-0.2;P=0.03)。
  • 两组出血事件相似。

关键数值与推荐

  • 主要终点7天早期神经功能恶化:双联抗血小板组72/1502(4.8%)vs 单用阿司匹林组95/1413(6.7%),风险差-1.9%(95%CI,-3.6至-0.2;P=0.03)。
  • 早期神经功能恶化定义为NIHSS评分较基线增加2分或以上,且非脑出血所致。
  • 改良意向性治疗人群包括所有至少完成1次疗效评估的随机参与者,不论治疗分配。

临床怎么用

  • 作者认为,对于急性轻中度缺血性卒中患者,双联抗血小板治疗可能是优于单用阿司匹林的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking. OBJECTIVE: To evaluate whether dual antiplatelet therapy is superior to single antiplatelet among patients with mild to moderate ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, open-label, blinded end point, randomized clinical trial conducted at 66 hospitals in China from December 20, 2016, through August 9, 2022. The date of final follow-up was October 30, 2022. The analysis was reported on March 12, 2023. Of 3065 patients with ischemic stroke, 3000 patients with acute mild to moderate stroke within 48 hours of symptom onset were enrolled, after excluding 65 patients who did not meet eligibility criteria or had no randomization outcome. INTERVENTIONS: Within 48 hours after symptom onset, patients were randomly assigned to receive clopidogrel plus aspirin (n = 1541) or aspirin alone (n = 1459) in a 1:1 ratio. MAIN OUTCOMES AND MEASURES: The primary end point was early neurologic deterioration at 7 days, defined as an increase of 2 or more points in National Institutes of Health Stroke Scale (NIHSS) score, but not as a result of cerebral hemorrhage, compared with baseline. The superiority of clopidogrel plus aspirin to aspirin alone was assessed based on a modified intention-to-treat population, which included all randomized participants with at least 1 efficacy evaluation regardless of treatment allocation. Bleeding events were safety end points. RESULTS: Of the 3000 randomized patients, 1942 (64.6%) were men, the mean (SD) age was 65.9 (10.6) years, median (IQR) NIHSS score at admission was 5 (4-6), and 1830 (61.0%) had a stroke of undetermined cause. A total of 2915 patients were included in the modified intention-to-treat analysis. Early neurologic deterioration occurred in 72 of 1502 (4.8%) in the dual antiplatelet therapy group vs 95 of 1413 (6.7%) in the aspirin alone group (risk difference -1.9%; 95% CI, -3.6 to -0.2; P = .03). Similar bleeding events were found between 2 groups. CONCLUSIONS AND RELEVANCE: Among Chinese patients with acute mild to moderate ischemic stroke, clopidogrel plus aspirin was superior to aspirin alone with regard to reducing early neurologic deterioration at 7 days with similar safety profile. These findings indicate that dual antiplatelet therapy may be a superior choice to aspirin alone in treating patients with acute mild to moderate stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02869009.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Chen HS, Cui Y, Wang XH, et al. Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38466274. doi:10.1001/jamaneurol.2024.0146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。